Neutrophil-dominant COPD, which is often associated with severe airflow limitation and corticosteroid resistance, may benefit from targeted agents such as CXCR2 antagonists (e.g., navarixin and ladarixin) or PDE4 inhibitors (e.g., roflumilast), which have shown promise in reducing neutrophilic inflammation and exacerbation [12,13,14,17]. Here, CXCR2 is linked to chronic obstructive pulmonary disease.